New Study Reports IceCure's ProSense® Boosts Immune Response Against Cancer: Enhances CD8+ T Cell Response
- None.
- None.
Insights
The recent findings from the study conducted at Case Western Reserve University School of Medicine and published in OncoImmunology are significant for the field of cryoimmunology. This research highlights the potential of IceCure Medical Ltd.'s ProSense® System to not only destroy tumors through cryoablation but also to potentially enhance the body's immune response against cancer. The activation of CD8+ T cells and their increased expression of CD25 and interferon gamma (IFNγ) suggest a promising avenue for immunotherapy, especially considering the importance of the adaptive immune system in targeting and eliminating cancer cells.
From a medical research standpoint, the role of the Piezo1 protein in T-cell activation during tumor immune-mediated rejection presents a novel aspect of cancer biology. Understanding the molecular pathways that contribute to the efficacy of cryoablation could lead to more tailored and effective treatment strategies. Moreover, the confirmation of the STING pathway's involvement in tumor immunity adds another layer of complexity and opportunity for enhancing cryoablation techniques with immunotherapeutic approaches.
However, it is essential to approach these findings with cautious optimism. While the mouse model provides valuable insights, the translation of these results to human clinical outcomes remains to be seen. The upcoming investigator-initiated trials will be crucial in determining the practical application and effectiveness of ProSense® in human patients. The long-term implications for patient survival, quality of life and potential reduction in healthcare costs due to less invasive procedures could be substantial if the human trials corroborate the preclinical data.
The study's implications for oncology are profound, particularly in the realm of minimally invasive treatments for solid tumors. Cryoablation, as performed by the ProSense® System, offers a less invasive alternative to surgical tumor removal, which could reduce patient morbidity and recovery times. The prospect of activating the immune system to continue fighting cancer cells after the procedure could transform the way oncologists approach tumor management, potentially offering a dual therapeutic benefit.
Understanding the immune system's role in cancer treatment is a rapidly evolving field. The enhancement of CD8+ T cells post-cryoablation indicates a synergistic effect that could lead to more durable responses in patients. This is especially relevant for tumors that are not easily resectable or for patients who are not candidates for surgery due to comorbidities.
As an oncologist, the next step would be to monitor the progress of human trials closely. The safety profile, immune response markers and overall survival rates will be key factors in evaluating the clinical viability of this technology. Moreover, the potential for cryoablation to induce systemic antitumor immunity could have implications for treating metastatic disease, a significant challenge in current cancer therapy.
IceCure Medical Ltd.'s announcement regarding the ProSense® System's ability to enhance the immune response could have a notable impact on the company's market position. As the medical community continues to seek innovative cancer treatments, technologies that offer minimally invasive procedures with added immunotherapeutic benefits are likely to capture the attention of both healthcare providers and investors.
The stock market often responds favorably to positive preclinical data, especially when it involves novel treatment modalities with the potential to disrupt standard care practices. However, investor sentiment will likely be tempered until further evidence from human trials is available. The scalability of ProSense® and its adoption rate across various healthcare systems will depend on its clinical efficacy, cost-effectiveness and the ability to integrate with existing treatment protocols.
Moreover, the unique mechanism of action of ProSense® could position IceCure Medical Ltd. as a pioneer in the cryoimmunology space, potentially opening up partnership opportunities with larger pharmaceutical companies interested in expanding their oncology portfolios. The long-term financial implications hinge on successful clinical outcomes and regulatory approvals, which would pave the way for commercialization and potential market expansion.
- Independent mouse study conducted at Case Western Reserve University School of Medicine, published in OncoImmunology, builds on body of evidence demonstrating cryoablation can activate the body's natural immune response by enhancing CD8+ T cells, which are an important arm of immune response
- Data support previous studies and suggest ProSense® may produce anti-cancer benefits in humans beyond tumor destruction during cryoablation procedure
The Piezo1 study involved performing cryoablation with ProSense® on tumor volumes of approximately 100 mm3 (diameter ~6 mm) using a mouse model. The cryoprobe was placed percutaneously directly on the tumor mass. The data demonstrates that cryoablation induces immune rejection by enhancing CD8+ T cell activation, a process dependent on T cell expression of Piezo1. Increased activation and responsiveness, potentially leading to a more robust immune response against abnormal cells, was detected up to 2 weeks after cryoablation, displayed as an increase in CD25 and interferon gamma (IFNγ) expression on CD8+ T cells.
In the field of cryoimmunology, cryoablation is known to induce potent T cell-dependent tumor rejection. Prior independent research using ProSense® to explore cryoablation's antitumor activity includes a study titled "Functional tumor cell-intrinsic STING, not host STING, drives local and systemic antitumor immunity and therapy efficacy following cryoablation" by Alshebremi et al published in August 2023 in the Journal of ImmunoTherapy of Cancer. The study demonstrated the unequivocal role of an ongoing and functional STING pathway as a major driver of local control and the systemic abscopal effects on advanced tumors following cryoablation.
"Preclinical data from both of these independent studies demonstrate the unique mechanism of action through which ProSense® induces the activation of immune cells which are critical to increasing the potential therapeutic benefits of cryoablation against solid tumors. These benefits extend beyond the destruction of the tumor through our minimally invasive procedure, by activating the immune system for weeks following the procedure," stated IceCure's Chief Executive Officer, Eyal Shamir. "These studies pave the way for analysis of immune response in the growing number of ProSense® cryoablation investigator-initiated trials in humans. As always, we are very grateful to the doctors conducting these independent studies that explore and confirm ProSense®'s mechanism of action and its benefits for patients."
About ProSense®
The ProSense® Cyroablation System provides a minimally invasive treatment option to destroy tumors by freezing them. The system uniquely harnesses the power of liquid nitrogen to create large lethal zones for maximum efficacy in tumor destruction in benign and cancerous lesions, including breast, kidney, lung, and liver.
ProSense® enhances patient and provider value by accelerating recovery, reducing pain, surgical risks, and complications. With its easy, transportable design and liquid nitrogen utilization, ProSense® opens that door to fast and convenient office-based procedure for breast tumors.
About IceCure Medical
IceCure Medical (Nasdaq: ICCM) develops and markets ProSense®, an advanced liquid-nitrogen-based cryoablation therapy for the treatment of tumors (benign and cancerous) by freezing, with the primary focus areas being breast, kidney, bone and lung cancer. Its minimally invasive technology is a safe and effective alternative to hospital surgical tumor removal that is easily performed in a relatively short procedure. The system is marketed and sold worldwide for the indications cleared and approved to date including in the
Forward Looking Statements
This press release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995 and other Federal and Israeli securities laws. Words such as "expects," "anticipates," "intends," "plans," "believes," "seeks," "estimates" and similar expressions or variations of such words are intended to identify forward-looking statements. For example, IceCure is using forward looking statement in this press release when it discusses: the expected plan and progress towards completion of the follow-up on the ICE3 clinical study in February 2024; evaluating all strategies to efficiently and effectively address the FDA's comments; and the expected 5-year results passed on the interim analysis of the ICE3 trial. Historic results of scientific research and clinical and preclinical trials do not guarantee that the conclusions of future research or trials will suggest identical or even similar conclusions. Because such statements deal with future events and are based on IceCure's current expectations, they are subject to various risks and uncertainties and actual results, performance, or achievements of IceCure could differ materially from those described in or implied by the statements in this press release. The forward-looking statements contained or implied in this press release are subject to other risks and uncertainties, many of which are beyond the control of the Company, including those set forth in the Risk Factors section of the Company's Annual Report on Form 20-F for the year ended December 31, 2022 filed with the SEC on March 29, 2023, and other documents filed with or furnished to the SEC which are available on the SEC's website, www.sec.gov. The Company undertakes no obligation to update these statements for revisions or changes after the date of this release, except as required by law.
IR Contact:
Email: investors@icecure-medical.com
Michael Polyviou
Phone: 732-232-6914
Todd Kehrli
Phone: 310-625-4462
Logo - https://mma.prnewswire.com/media/1941429/IceCure_Logo.jpg
View original content:https://www.prnewswire.com/news-releases/new-study-reports-icecures-prosense-boosts-immune-response-against-cancer-enhances-cd8-t-cell-response-302025257.html
SOURCE IceCure Medical
FAQ
What is the name of the company mentioned in the press release and its ticker symbol?
What is the study published in OncoImmunology about?
Where was the study conducted?
What is the unique mechanism of action demonstrated by ProSense® according to IceCure's CEO?
What does the study pave the way for according to IceCure's CEO?
